Manulife stock rises over 2% as strong earnings and upbeat outlook boost confidence

Traders Union
All News
Stocks
Manulife rises 2.01% today on earnings

Highlights

Manulife posted strong quarterly results, with both free cash flow and earnings per share exceeding analyst expectations.
The company is investing in AI and technology initiatives worth USD 1 billion by 2027 and expanded partnerships in Asia and North America.
Manulife stock advanced C$1.26 or 2.01%, remains in a bullish long-term trend, and is expected to trade between C$62.77 to C$64.78 over the next five days.

Earnings beat and strategic investments drive positive market sentiment

Manulife reported strong quarterly earnings, with free cash flow and earnings per share surpassing analyst consensus. Operational performance was solid across insurance, wealth, and asset management operations, highlighting the company’s diversified model and market resilience. Manulife is investing in technology, including an AI platform targeting USD 1 billion in value by 2027, and maintains a robust capital position. Recent collaborations in Asia and North America further demonstrate its global strategy.

Anton Kharitonov, expert at Traders Union, sees the 2.01% gain in Manulife as mainly driven by optimistic earnings headlines, but he urges caution. Although price is above all key moving averages, several technical oscillators are overbought and momentum may be stretched. He points to rising intraday volatility as a sign of potential reversal risk. Operational gains and technology investments look promising, but short-term traders face elevated downside risk as sentiment appears crowded. "Despite strong news, I remain cautious on near-term upside — an overbought profile calls for careful position management."

Viktoras Karapetjanc, expert at Traders Union, highlights the positive momentum in Manulife after a strong earnings beat and technology-driven growth initiatives. He notes the company's diversified business model and active global strategy as key strength factors. Strong multi-segment performance and robust capital position suggest the bullish structure remains intact. "Further growth is expected as Manulife capitalizes on operational resilience and new partnerships."

Jainam Mehta, market strategist, observes that Manulife's technical structure is robust, with price action above all major moving averages and a recent upside gap. He points to bullish signals from MACD alongside overbought risk from oscillators, suggesting a potential breakout or a mean-reversion setup. Mehta says, "I see scope for tactical trades near resistance or a contrarian pullback, depending on intraday confirmation."

Multiple indicators flag overbought risk as resistance nears

Manulife trades above its 20-day (C$61.38), 50-day (C$60.83), and 200-day (C$55.04) moving averages, reinforcing strength in the short, medium, and long term. The nearest resistance stands at C$64.78, while support is set by today’s high at C$63.32, confirming a bullish long-term trend through moving average alignment. Momentum indicators are mostly constructive: the MACD signals a buy and the Average Directional Index (ADX) remains neutral. The Relative Strength Index (RSI) is in buy territory. However, the Stochastic RSI, Commodity Channel Index (CCI), and Bull/Bear Power (BBP) all show overbought conditions. Positive Bull/Bear Power and the Awesome Oscillator (AO) both support ongoing bullish momentum. The stock gained C$1.26 or 2.01% after an upside gap, with price closing near the session high and intraday volatility at 0.88%, signaling strong buyer pressure. Several oscillators point to overbought risk, but the intraday tone remains bullish.

Earlier, analysts noted that Manulife Financial exhibited sustained technical strength and a broadly bullish outlook. The current article strengthens this view with new earnings data and operational developments, highlighting C$64.78 as the key resistance level for potential breakout in the days ahead.

Source of Data: MFC Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.